Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Lars Fruergaard Jørgensen
CEOLars Fruergaard Jørgensen
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1931
Founded1931
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
289.57B
Market cap289.57B
Price-Earnings ratio
19.04
Price-Earnings ratio19.04
Dividend yield
1.84%
Dividend yield1.84%
Average volume
7.14M
Average volume7.14M
High today
$66.21
High today$66.21
Low today
$64.16
Low today$64.16
Open price
$65.67
Open price$65.67
Volume
8.05M
Volume8.05M
52 Week high
$139.74
52 Week high$139.74
52 Week low
$57.00
52 Week low$57.00

NVO News

TipRanks 3d
Novo Nordisk’s Mim8 Study: A Potential Game-Changer in Haemophilia Treatment

Novo Nordisk ((DE:NOVA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

Benzinga 3d
Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs fundamentally altering consumer food purchasing patterns a...

Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles
TipRanks 3d
Hims & Hers Faces Legal Storm Post Novo Nordisk Breakup

Hims & Hers Health (HIMS) is under growing legal pressure following the collapse of its partnership with pharmaceutical giant Novo Nordisk (NVO). The fallout ha...

Analyst ratings

66%

of 32 ratings
Buy
65.6%
Hold
25%
Sell
9.4%

More NVO News

TipRanks 4d
Novo Nordisk’s New Study on NNC0519-0130: A Potential Game-Changer for Diabetes Treatment?

Novo Nordisk ((DE:NOVA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

Benzinga 4d
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said tha...

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
TipRanks 6d
Clever Culture Systems Secures Instrument Sale to Novo Nordisk for Evaluation

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.